Reuters logo
BRIEF-Voyager Therapeutics gains full development and commercial rights to VY-AADC
October 30, 2017 / 8:21 PM / 24 days ago

BRIEF-Voyager Therapeutics gains full development and commercial rights to VY-AADC

Oct 30 (Reuters) - Voyager Therapeutics Inc:

* Voyager Therapeutics announces update to parkinson’s disease program

* Voyager Therapeutics - ‍Sanofi Genzyme informed Voyager that it has decided not to exercise its rights to ‍VY-AADC​ program​

* Voyager Therapeutics says ‍as a result, it gains full worldwide development and commercial rights to VY-AADC for treatment of advanced parkinson’s disease​

* Voyager Therapeutics - ‍global, pivotal phase 2-3 program for VY-AADC on track to dose first patient during Q2 of 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below